Ribonucleic Acid News and Research

RSS

Evaluating tixagevimab plus cilgavimab against SARS-CoV-2

Researchers assessed the neutralizing activity against SARS-CoV-2 Omicron variant after tixagevimab plus cilgavimab (T+C) administration.

30 May 2022

Study investigates whether people with breakthrough SARS-CoV-2 infection develop post-acute sequelae

Researchers characterized long COVID-19 after a breakthrough COVID-19 infection.

30 May 2022

Researchers identify a human monoclonal antibody that could broadly neutralize several variants of SARS-CoV-2, SARS-CoV, and other coronaviruses

Researchers identified 10-40, a human monoclonal antibody with potent neutralizing activity against SARS-CoV, SARS-CoV-2, and related sarbecoviruses.

30 May 2022

Exploring virological profiles of recently emerged SARS-CoV-2 Omicron variants

Researchers explored the virological profiles of novel SARS-CoV-2 Omicron variants.

30 May 2022

Continuous evolution of SARS-CoV-2 Omicron variant yielding immune evasive subvariants

Researchers reported findings of a systematic antigenic analysis of the circulating SARS-CoV-2 Omicron subvariants such as BA.2.12.1, BA.4, and BA.5.

30 May 2022

Direct comparison of immune memory responses to four COVID-19 vaccines

Researchers evaluated host immune responses to four COVID-19 vaccines representing three different vaccine technology platforms, focusing on immune memory responses.

30 May 2022

Hemodialysis patients obtain a robust humoral response from a third dose of the BNT162b2 vaccine, study finds

Researchers assessed the humoral immune responses generated by the third Pfizer-BioNTech BNT162b2 mRNA vaccination against SARS-CoV-2 among hemodialysis patients.

30 May 2022

Researchers evaluate atovaquone as a COVID-19 treatment

Researchers evaluated a drug, atovaquone, for COVID-19 treatment.

30 May 2022

2-Deoxy-D-glucose may inhibit coronaviruses and rhinoviruses

Scientists demonstrated the use of 2-deoxy-D-glucose (2-DG) as a wide-spectrum antiviral agent targeting viruses such as SARS-CoV-2.

27 May 2022

Nanotechnology enhanced DNA-chip for SARS-CoV-2 detection with variant differentiation

Researchers differentiated between SARS-CoV-2 variants using nanotechnology.

26 May 2022

Mucosal COVID vaccine candidate powerfully protective in macaques

A recent research paper posted to the bioRxiv* preprint server illustrated the protective efficacy of the intranasal pediatric parainfluenza virus-vectored coronavirus disease 2019 (COVID-19) vaccine prospect, B/HPIV3/S-6P, in macaques.

26 May 2022

Study shows glomerulonephritis after SARS-CoV-2 mRNA vaccination likely coincidental

In a recent study posted to the medRxiv* pre-print server, researchers assessed whether messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccines increase the incidence of glomerulonephritis against the null hypothesis stating any observed temporal association between the two phenomena was purely coincidental.

26 May 2022

Study measures viral antigen and inflammatory biomarkers in CSF of COVID-19 patients in relation to neurologic symptoms and disease severity

Researchers investigated the impact of coronavirus disease 2019 (COVID-19) on biomarkers in the cerebrospinal fluid (CSF).

25 May 2022

Review addresses the need for innovative adjuvant approaches and delivery strategies for the advancement of new mucosal vaccines

Researchers reviewed available mucosal vaccines discussing the current challenges and ways to advance the existing approaches.

25 May 2022

The effectiveness of molnupiravir and nirmatrelvir/ritonavir in reducing hospitalization and deaths in non-hospitalized COVID-19 patients

Researchers assessed the effectiveness of two orally administered antiviral medications, nirmatrelvir/ritonavir, and molnupiravir, in decreasing hospitalization and deaths among real-world non-hospitalized COVID-19 patients in Hong Kong.

25 May 2022

Gut microbiota linked to immunocompromised people's variable response to SARS-CoV-2 vaccination

In a recent study posted to the Research Square* preprint server, researchers assessed whether disturbances in the gut microbiota weaken the serological response to the coronavirus disease 2019 (COVID-19) vaccine in inflammatory bowel disease (IBD) patients.

25 May 2022

A study on the safety of BNT162b2 COVID vaccine in children under five

In a recent research paper posted to the medRxiv* preprint server, scientists explored the safety of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BNT162b2 vaccine in children under five years of age.

25 May 2022

Association between reactogenicity and immunogenicity in SARS-CoV-2 mRNA-1273 vaccination

A recent study currently under review at Scientific Reports journal and posted to the Research Square* preprint server demonstrated a potential positive correlation between reactogenicity and immunogenicity of coronavirus disease 2019 (COVID-19) vaccination.

25 May 2022

Immunogenicity of BNT162b2 COVID-19 vaccine in melanoma patients receiving immunotherapy

In a recent study under review at the Scientific Reports journal and posted to the Research Square* preprint server, researchers evaluated the efficacy of messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccine BNT162b2 in cancer patients under treatment with immune checkpoint inhibitors (ICIs).

25 May 2022

Computational modeling fine tunes RBD-1C aptamer against SARS-CoV-2 S protein

Researchers used the SARS-CoV-2 sequence against aptamers to perform the in silico selection of an aptamer against the SARS-CoV-2 S protein.

24 May 2022

Ribonucleic Acid News and Research

Evaluating tixagevimab plus cilgavimab against SARS-CoV-2

Study investigates whether people with breakthrough SARS-CoV-2 infection develop post-acute sequelae

Researchers identify a human monoclonal antibody that could broadly neutralize several variants of SARS-CoV-2, SARS-CoV, and other coronaviruses

Exploring virological profiles of recently emerged SARS-CoV-2 Omicron variants

Continuous evolution of SARS-CoV-2 Omicron variant yielding immune evasive subvariants

Direct comparison of immune memory responses to four COVID-19 vaccines

Hemodialysis patients obtain a robust humoral response from a third dose of the BNT162b2 vaccine, study finds

Researchers evaluate atovaquone as a COVID-19 treatment

2-Deoxy-D-glucose may inhibit coronaviruses and rhinoviruses

Nanotechnology enhanced DNA-chip for SARS-CoV-2 detection with variant differentiation

Mucosal COVID vaccine candidate powerfully protective in macaques

Study shows glomerulonephritis after SARS-CoV-2 mRNA vaccination likely coincidental

Study measures viral antigen and inflammatory biomarkers in CSF of COVID-19 patients in relation to neurologic symptoms and disease severity

Review addresses the need for innovative adjuvant approaches and delivery strategies for the advancement of new mucosal vaccines

The effectiveness of molnupiravir and nirmatrelvir/ritonavir in reducing hospitalization and deaths in non-hospitalized COVID-19 patients

Gut microbiota linked to immunocompromised people's variable response to SARS-CoV-2 vaccination

A study on the safety of BNT162b2 COVID vaccine in children under five

Association between reactogenicity and immunogenicity in SARS-CoV-2 mRNA-1273 vaccination

Immunogenicity of BNT162b2 COVID-19 vaccine in melanoma patients receiving immunotherapy

Computational modeling fine tunes RBD-1C aptamer against SARS-CoV-2 S protein

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News